iCAD Inc (NASDAQ:ICAD) shares traded up 2.5% on Wednesday . The company traded as high as $8.11 and last traded at $8.07, 10,669 shares changed hands during trading. A decline of 98% from the average session volume of 475,480 shares. The stock had previously closed at $7.87.
A number of research firms have commented on ICAD. JMP Securities began coverage on shares of iCAD in a research report on Wednesday, February 5th. They set an “outperform” rating and a $15.00 target price on the stock. Craig Hallum raised their target price on shares of iCAD from $9.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Lake Street Capital began coverage on shares of iCAD in a research report on Thursday, January 9th. They set a “buy” rating and a $14.00 target price on the stock. Finally, Dougherty & Co began coverage on shares of iCAD in a research report on Friday, December 20th. They set a “buy” rating and a $10.00 target price on the stock. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $13.50.
The company has a current ratio of 1.55, a quick ratio of 1.41 and a debt-to-equity ratio of 3.45. The firm has a market cap of $166.59 million, a PE ratio of -12.16 and a beta of 0.18. The business’s 50-day simple moving average is $10.66 and its 200 day simple moving average is $8.31.
Several institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC grew its position in shares of iCAD by 0.5% in the 4th quarter. Renaissance Technologies LLC now owns 603,270 shares of the technology company’s stock worth $4,687,000 after buying an additional 3,100 shares during the last quarter. Parkman Healthcare Partners LLC purchased a new position in shares of iCAD in the 4th quarter worth approximately $4,667,000. EAM Investors LLC grew its position in shares of iCAD by 4.9% in the 4th quarter. EAM Investors LLC now owns 350,880 shares of the technology company’s stock worth $2,726,000 after buying an additional 16,308 shares during the last quarter. Geode Capital Management LLC grew its position in shares of iCAD by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 138,635 shares of the technology company’s stock worth $1,077,000 after buying an additional 2,271 shares during the last quarter. Finally, Credit Suisse AG purchased a new position in shares of iCAD in the 4th quarter worth approximately $527,000. 27.70% of the stock is currently owned by hedge funds and other institutional investors.
iCAD Company Profile (NASDAQ:ICAD)
iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy.
Further Reading: Quiet Period Expirations
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.